GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lifecore Biomedical Inc (NAS:LFCR) » Definitions » Gross Margin %

Lifecore Biomedical (Lifecore Biomedical) Gross Margin % : 32.97% (As of May. 2023)


View and export this data going back to 1996. Start your Free Trial

What is Lifecore Biomedical Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Lifecore Biomedical's Gross Profit for the three months ended in May. 2023 was $8.4 Mil. Lifecore Biomedical's Revenue for the three months ended in May. 2023 was $25.5 Mil. Therefore, Lifecore Biomedical's Gross Margin % for the quarter that ended in May. 2023 was 32.97%.


The historical rank and industry rank for Lifecore Biomedical's Gross Margin % or its related term are showing as below:

LFCR' s Gross Margin % Range Over the Past 10 Years
Min: 12.13   Med: 15.9   Max: 38.6
Current: 20.52


During the past 13 years, the highest Gross Margin % of Lifecore Biomedical was 38.60%. The lowest was 12.13%. And the median was 15.90%.

LFCR's Gross Margin % is ranked worse than
87.53% of 986 companies
in the Drug Manufacturers industry
Industry Median: 46.375 vs LFCR: 20.52

Lifecore Biomedical had a gross margin of 32.97% for the quarter that ended in May. 2023 => Competition eroding margins

The 5-Year average Growth Rate of Gross Margin for Lifecore Biomedical was 19.00% per year.


Lifecore Biomedical Gross Margin % Historical Data

The historical data trend for Lifecore Biomedical's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lifecore Biomedical Gross Margin % Chart

Lifecore Biomedical Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.53 24.61 38.60 35.11 27.10

Lifecore Biomedical Quarterly Data
Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.18 14.42 18.32 21.66 32.97

Competitive Comparison of Lifecore Biomedical's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Lifecore Biomedical's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lifecore Biomedical's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lifecore Biomedical's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Lifecore Biomedical's Gross Margin % falls into.



Lifecore Biomedical Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Lifecore Biomedical's Gross Margin for the fiscal year that ended in May. 2023 is calculated as

Gross Margin % (A: May. 2023 )=Gross Profit (A: May. 2023 ) / Revenue (A: May. 2023 )
=28 / 103.269
=(Revenue - Cost of Goods Sold) / Revenue
=(103.269 - 75.284) / 103.269
=27.10 %

Lifecore Biomedical's Gross Margin for the quarter that ended in May. 2023 is calculated as


Gross Margin % (Q: May. 2023 )=Gross Profit (Q: May. 2023 ) / Revenue (Q: May. 2023 )
=8.4 / 25.521
=(Revenue - Cost of Goods Sold) / Revenue
=(25.521 - 17.106) / 25.521
=32.97 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Lifecore Biomedical  (NAS:LFCR) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Lifecore Biomedical had a gross margin of 32.97% for the quarter that ended in May. 2023 => Competition eroding margins


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Lifecore Biomedical Gross Margin % Related Terms

Thank you for viewing the detailed overview of Lifecore Biomedical's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Lifecore Biomedical (Lifecore Biomedical) Business Description

Traded in Other Exchanges
N/A
Address
3515 Lyman Boulevard, Chaska, MN, USA, 55318
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid.
Executives
Raymond T. White director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Holdings, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, L.p. Ii director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, L.p. I director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Asset Management, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Christopher S Kiper director 12121 WILSHIRE BLVD, SUITE 1240, LOS ANGELES CA 90025
Nathaniel Calloway director C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734
Wynnefield Partners Small Cap Value Lp I 10 percent owner 450 SEVENTH AVENUE, SUITE 509, NEW YORK NY 10123
Raymond H Diradoorian director C/O LANDEC CORPORATION, 2811 AIRPARK DRIVE, SANTA MARIA CA 93455
Joshua Schechter director C/O THE PANTRY, INC., 305 GREGSON DRIVE, CARY NC 27511
Patrick D Walsh director 14282 FRANKLIN AVE., TUSTIN CA 92780
John D Morberg officer: Chief Financial Officer C/O LANDEC CORPORATION, 2811 AIRPARK DRIVE, SANTA MARIA CA 93455
Albert D. Bolles director CONAGRA FOODS, INC., ONE CONAGRA DRIVE, MS 1-330, OMAHA NE 68102
James G Hall officer: Executive Vice President 3515 LYMAN BLVD., CHASKA MN 55318